Myeloma Paper of the Day, September 25th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Small correlative study of pomalidomide in myeloma patients finds that it influences the T-cell repertoire, particularly in the CD4 + subpopulation during the later stages of treatment.”

Source: Robert Orlowski/X

Pomalidomide in patients with multiple myeloma: potential impact on the reconstitution of a functional T-cell immunity

Authors: Jiaxin Shen, Francesca Senes, Xiaofen Wen, Patrizia Monti, Shaoze Lin, Claudia Pinna, Andrea Murtas, Luigi Podda, Giuseppina Muntone, Gianni Tidore, Claudia Arru, Luca Sanna, Salvatore Contini, Patrizia Virdis, Leonardo Antonio Sechi and Claudio Fozza.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.